Exploring the effects of intermittent hypoxia on colorectal cancer
Official title: Exploratory Study of the Impact of Intermittent Hypoxia Intervention on Patients With Colorectal Cancer
Run by Capital Medical University · NCT06584318 · Data updated 2026-11-12
This study is testing if breathing low oxygen levels for short periods can help people with colorectal cancer by boosting their immune system and slowing down tumor growth.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 20 (estimated) |
| Sponsor | Capital Medical University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Status | Recruiting |
| Started | March 1, 2024 |
| Main results expected | March 30, 2026 |
| Study ends | April 30, 2026 |
| Registry record updated | May 28, 2025 |
| Trial ID | NCT06584318 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults aged 18 to 65 with stage I or II colorectal cancer who can provide informed consent.
✕Probably not a fit
Patients with a history of significant comorbidities or recent cancer treatments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the safety and efficacy of intermittent hypoxia intervention in patients diagnosed with colorectal cancer. The approach involves periodic exposure to low oxygen levels, which may enhance the body's immune response and potentially inhibit tumor progression. The study employs a non-randomized self-controlled design to assess the impact of this intervention on cancer outcomes. Previous animal studies have indicated promising results, suggesting that intermittent hypoxia could reduce inflammation and improve immune function in the context of cancer.
Why it matters
Potential benefit: If successful, this intervention could provide a novel therapeutic approach to enhance immune function and inhibit tumor growth in colorectal cancer patients.
How similar studies have gone: While the use of intermittent hypoxia has shown promise in animal models, this approach in human colorectal cancer patients is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with colorectal cancer between ages of 18 and 65 years. * Colorectal cancer stage Ⅰ,Ⅱ. * Subjects or their legally authorized representative can provide informed consent. Exclusion Criteria: * History of cardiovascular, cerebrovascular, dermatological, and hematological diseases. * History of pulmonary, hepatic, kidney, dermatologic and hematologic diseases. * History of pregnancy, hypertension, diabetes mellitus, obesity, sleep apnea and neurological disorders. * History of substance abuse. * Participating in other drug or medical device studies. * History of organ transplantation, including allogeneic stem cell and immune cell transplantation. * Recent severe infection within 4 weeks. * Received cancer treatment, including chemotherapy and radiotherapy, within 4 weeks. * Underwent major surgery within 28 days.
Where it's running
-
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China Recruiting
Study contacts
- Study coordinator: Yuan Wang, M.D.
- Email: wilma0106@163.com
- Phone: +86-13581567815
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Knife-assisted full-thickness resection for rectal lesions in a multicenter setting
A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.
-
Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery
Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.
-
Liver transplantation for colorectal cancer with liver metastases
This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.
-
LTZ-232: a first-in-human test in advanced colorectal and other solid tumors
A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.